John Reilly is Chief Executive Officer of Damona Pharmaceuticals. Mr. Reilly brings extensive experience in the biotechnology industry, with deep knowledge and expertise in corporate strategy, business development, and leading teams in preclinical R&D and clinical development. Most recently, he served as CEO, President, and a member of the board of directors of Apic Bio, a gene therapy company focused on rare neurodegenerative and liver diseases. At Apic Bio, Mr. Reilly advanced the company’s ALS program to IND approval and orchestrated a global licensing agreement.

Mr. Reilly previously served as Vice President of Business Development at Tetragenetics, which was acquired by Abcellera (Nasdaq: ABCL). While at Tetragenetics, he led strategic partnering efforts with a number of companies including Amgen, Pfizer, and MedImmune and helped transform the company from a drug discovery platform to a product-focused company. Prior to Tetragenetics, Mr. Reilly co-founded and served as CEO of Gendyne Therapeutics and conducted research in the Department of Microbiology and Immunology in Cornell University’s College of Veterinary Medicine. Mr. Reilly is active in the Massachusetts biotechnology ecosystem, having served as a mentor for the MassBioDrive Program, and he sits on the committee for Cornell Innovation & Venture Advisors (CIVA). He received a B.A. from Hamilton College and M.S. and M.B.A. degrees from Cornell University.

Dev Chopra, B.Eng., MBA, ICD.D

Dev Chopra is a corporate director with significant senior leadership experience in the broader public sector. His most recent appointments include Executive Vice President, Clinical Programs and Executive Vice President Corporate Services at the Centre for Addiction and Mental Health (CAMH), and Chief Administrative Officer at the Temerty Faculty of Medicine at University of Toronto. Prior to this, he had an extensive career in the electricity generation sector holding the position of Vice President, Finance at Ontario Power Generation. A mechanical engineer by training, Dev holds an MBA from McGill University, and has attended executive development program at Harvard University. Dev has served as a director on diverse boards, a number of these in health care, and holds an ICD.D designation from the Institute of Corporate Directors.

Jacki Jenuth, Ph.D.

With over 20 years of life science, IT and business development executive-level experience, Jacki is a key member of the senior investment team sourcing, conducting diligence on, structuring deals terms for and working closely at the board level with portfolio companies. Jacki has a strong reputation for providing the focus, clarity and cohesion required to drive projects from efficient inception to effective completion. Jacki focuses on early to mid-stage private companies involved in all aspects drug discovery and development utilizing a variety of platforms from complex biologics to small molecules in a variety of indications including oncology, neurology, rare disorders and inflammatory diseases. In addition to her investment activities, Jacki is also Lumira’s COO with responsibilities that include directing all aspects of Lumira Ventures’ information technology initiatives having developed a world class venture capital analytics platform. Prior to joining Lumira Ventures, Jacki worked at Base4 and Open Text Inc. where she developed, sold and provided support for enterprise content management solutions targeted to the biotechnology and pharmaceutical industry in North America and Europe. Jacki has published several scientific articles and two book chapters, and is the recipient of three major academic research awards.

Sri Teja Mullapudi, Ph.D.

Teja is a Principal with Noetic Fund, and has helped raise and deploy $60M+ capital towards the goal of improving the mental health treatment landscape, across therapeutics, devices, digital modalities.  Previously, he co-founded & led business development for a neuropsychiatry-focused biotech company; and is experienced in early stage investment opportunity analyses across therapeutic areas from TIAP (MaRS Innovation). Teja has a Ph.D. (summa) in biology from the Max Planck Society with several research publications and awards, and is trained as a Biotechnology engineer from the Indian Institute of Technology Madras, India.  

Etienne Sibille, Ph.D.

Dr. Sibille is the acting CEO, CSO, and co-founder of DAMONA. He is also a Senior Scientist at the Campbell Family Mental Health Research Institute and holds the Campbell Family Chair in Clinical Neuroscience at CAMH. Dr. Sibille is also a Professor in the Department of Psychiatry and the Department of Pharmacology and Toxicology at the University of Toronto. Dr. Sibille’s goals have consistently focused on translational research aimed at identifying the cellular and molecular bases of depression, specifically of the mood, affect, and cognitive components of the illness in order to develop novel therapeutic avenues.